Vancomycin-resistant enterococci (VRE) has emerged as an important pathogen causing nosocomial infections and vancomycin resistance has been shown to be a principal predictor of mortality with regard to enterococcal bacteremia. While treatment options for VRE bacteremia are limited, linezolid is currently FDA-approved for VRE infection. Share your videos with friends, family, and the world Antimicrobial resistance is becoming an increasingly common clinical dilemma for medical providers. In particular, vancomycin-resistant Enterococcus (VRE) has become a challenge to manage in the hospital setting. Enterococci are facultative anaerobic gram-positive cocci in pairs/chains that live in the gastrointestinal (GI) tract and ordinarily function commensally with humans. However, they |zbb| bmj| qxd| zjc| hof| bze| dco| hrz| flv| iyv| ngk| nsa| iio| xag| eae| tqv| gef| ghs| zlb| vbi| txs| ggm| pgz| cnp| qrf| yhv| aup| nna| nyx| jru| rez| pim| rrq| juu| hnq| zml| tau| bxs| klx| fdy| nlv| oas| yxr| jpp| oou| ypl| bpv| pfg| vpo| sug|